Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients: The Phase 2 MARBLE Randomized Clinical Trial - PubMed
21 hours ago
- #phase 2 clinical trial
- #postoperative delirium
- #APOE mimetic peptide
- The Phase 2 MARBLE trial assessed the safety and feasibility of the apoE mimetic peptide CN-105 in reducing postoperative delirium and neuroinflammation in older adults (age 60+).
- In this triple-blind randomized trial, CN-105 was compared to placebo in 186 patients undergoing noncardiac or nonintracranial surgery.
- CN-105 showed similar rates of grade 2+ adverse events to placebo (76.6% vs 87.8%) but had fewer such events per patient (median 1 vs 2, P=.03).
- Drug administration was feasible, with over 93% of doses given within 90 minutes of schedule in both groups.
- Postoperative delirium incidence was lower with CN-105 (19.3%) vs placebo (26.5%), but the difference was not statistically significant (P=.29).
- CN-105 did not significantly reduce delirium severity or changes in cerebrospinal fluid cytokine levels compared to placebo.
- The trial concluded that CN-105 was safe and feasible, warranting a Phase 3 trial to further evaluate efficacy in reducing postoperative adverse events and delirium.